Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancer.
Nishita TripathiVinay Mathew ThomasNicolas SayeghGeorges GebraelBeverly ChigariraYeonjung JoHaoran LiKamal K SahuRoberto NussenzveigBlake NordbladUmang SwamiNeeraj AgarwalBenjamin L MaughanPublished in: The Prostate (2023)
In this real-world study, mCRPC patients with AR alterations on cfDNA had inferior OS after disease progression on the first ARPI, compared to those who did not, and may impact outcomes on a subsequent ARPI but not on subsequent taxane-based therapy received. By providing survival estimates for patients with or without AR alterations, our data may aid in patient counseling, prognostication, treatment decision, and for designing future clinical trials in this setting.
Keyphrases
- clinical trial
- small cell lung cancer
- squamous cell carcinoma
- case report
- big data
- stem cells
- single cell
- gene expression
- randomized controlled trial
- open label
- adipose tissue
- bone marrow
- human immunodeficiency virus
- replacement therapy
- cell therapy
- artificial intelligence
- glycemic control
- metastatic breast cancer
- hiv testing